Alnylam Research on miRNAs Featured in The New England Journal of Medicine
News Mar 20, 2006
Alnylam Pharmaceuticals, Inc. has announced that its research on therapeutic silencing of microRNAs was featured in an article published in the March 16, 2006 issue of The New England Journal of Medicine.
The article titled 'MicroRNAs as Therapeutic Targets' was authored by Dr. Michael Czech, Chair of the Program in Molecular Medicine at the University of Massachusetts Medical School, and discussed clinical applications for intervening with microRNAs.
Research by Alnylam and its collaborators at The Rockefeller University has demonstrated that miRNAs can be specifically silenced by using antagomirs, a class of oligonucleotide drugs.
Alnylam believes this approach creates the opportunity to design antagomirs that target miRNAs involved in the cause or pathway of human diseases, such as cancer and viral infection.
"We're thrilled to have the importance of miRNAs and Alnylam's own work in this field recognized and reviewed in one of the world's leading medical journals," said John Maraganore, Ph.D., President and Chief Executive Officer of Alnylam.
"We believe that the opportunity to target miRNAs involved in human disease with antagomirs is an important extension of our platform to harness the RNAi pathway for discovery of innovative medicines."
In a new study in cells, University of Illinois researchers have adapted CRISPR gene-editing technology to cause the cell’s internal machinery to skip over a small portion of a gene when transcribing it into a template for protein building. This gives researchers a way not only to eliminate a mutated gene sequence, but to influence how the gene is expressed and regulated.
Researchers published today a detailed description of the complete genome of bread wheat, the world's most widely-cultivated crop. This work will pave the way for the production of wheat varieties better adapted to climate challenges, with higher yields, enhanced nutritional quality and improved sustainability.